AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
Portfolio Pulse from Avi Kapoor
Jim Cramer expressed his preference for Abbott Laboratories over AbbVie, despite AbbVie's strong performance. UBS raised AbbVie's price target. Oracle's data center business is praised, and Core Scientific is likened to Palantir. Clover Health's Medicare plans received a higher Star rating. GXO Logistics is valued for its new partnership, and Sweetgreen is anticipated to release its Q3 results.
October 17, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jim Cramer favors Abbott Laboratories over AbbVie, indicating a positive sentiment towards the company.
Cramer's preference for Abbott Laboratories over AbbVie suggests a positive sentiment, which could lead to a short-term price increase.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Clover Health's Medicare Advantage plans received a higher Star rating, which could positively impact future payments.
The improved Star rating for Clover Health's Medicare plans could lead to increased future payments, positively impacting the stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60
POSITIVE IMPACT
Core Scientific is compared to Palantir by Jim Cramer, and its price target was raised by B. Riley Securities.
The comparison to Palantir and a raised price target suggest a positive outlook for Core Scientific, potentially leading to a price increase.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 50
POSITIVE IMPACT
GXO Logistics is valued by Jim Cramer, and the company announced a new transport partnership with Matalan.
Cramer's positive remarks and the new partnership announcement could enhance GXO's market position, potentially leading to a price increase.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 50
POSITIVE IMPACT
Oracle's data center business is praised by Jim Cramer, and the company launched a new cloud-based solution for healthcare data exchange.
Cramer's positive remarks on Oracle's data center business and the launch of a new product could boost investor confidence, leading to a potential price increase.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
Sweetgreen is praised by Jim Cramer, and the company is set to release its Q3 financial results soon.
Cramer's positive sentiment and the upcoming earnings release could generate investor interest, potentially leading to a price increase.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
AbbVie is performing well, with UBS raising its price target from $185 to $195. However, Jim Cramer prefers Abbott Laboratories over AbbVie.
Despite AbbVie's strong performance and a raised price target, Jim Cramer's preference for Abbott Laboratories may neutralize the positive impact of the price target increase.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80